BIOLIDICS LIMITED
(Company Registration No.: 200913076M)
(Incorporated in the Republic of Singapore)

ACQUISITION OF THE ENTIRE ISSUED AND PAID-UP SHARE CAPITAL OF BIOMEDICS LABORATORY PTE. LTD. –

RECEIPT OF LISTING AND QUOTATION NOTICE FROM THE SINGAPORE EXCHANGE SECURITIES TRADING LIMITED ("SGX-ST")

The board of directors (the "**Board**") of Biolidics Limited (the "**Company**") refers to the Company's announcement dated 28 February 2023 ("**Announcement**") in relation to the entry into of a partial settlement deed with Clearbridge BSA Pte. Ltd. ("**CBSA**") on the partial settlement of the deferred consideration owing by the Company to CBSA in connection with the acquisition of the entire issued and paid-up share capital of Biomedics Laboratory Pte. Ltd..

Capitalised terms used and not defined herein shall have the same meanings ascribed to them in the Announcement.

Further to the Announcement, the Board wishes to announce that the Company has, on 16 March 2023, received the listing and quotation notice ("**LQN**") from the SGX-ST for the dealing in, listing of and quotation for the 37,500,000 Consideration Shares on the Catalist board of the SGX-ST. The LQN is subject to the Company's compliance with the SGX-ST's listing requirements.

The LQN is not to be taken as an indication of the merits of the Consideration Shares, the Acquisition, the Company and/or its subsidiaries.

The Consideration Shares are to be issued and allotted pursuant to and within the limits of the general share issue mandate to issue new Shares whether by way of rights, bonus or otherwise, which was approved by shareholders of the Company at the annual general meeting of the Company held on 28 April 2022.

A separate announcement will be released by the Company upon the allotment and issuance of the Consideration Shares.

By Order of the Board

Song Tang Yih
Executive Director and Chief Executive Officer
16 March 2023

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the **"Sponsor"**), for compliance with Rules 226(2)(b) and 753(2) of the SGX-ST Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr. Lim Hoon Khiat, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.